// App-Quantinova.ai

4110 : The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results.

Researchers

Presenter

  • Daniel M. Halperin

Principal Investigators

  • Melissa Lynne Johnson

  • Jennifer A. Chan

  • Lowell L. Hart

  • Natalie Cook

  • Vipul M. Patel

  • Benjamin L. Schlechter

  • Judith Cave

  • Afshin Dowlati

  • Lawrence Scott Blaszkowsky

  • Tim Meyer

  • Jennifer Rachel Eads

  • Daniel Culp

  • Kristina Kriksciukaite

  • Laura Mei

  • Mark Bilodeau

  • Jeffrey Bloss

  • Matthew H. Kulke

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Sarah Cannon Research Institute, Nashville, TN

  • Dana-Farber Cancer Institute, Boston, MA

  • Florida Cancer Specialists and Research Institute, Sarasota, FL

  • University of Manchester, Manchester, United Kingdom

  • Gaston Hem and Onc, Gastonia, NC

  • Southampton University Hospitals NHS Trust, Southhampton, United Kingdom

  • Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH

  • Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

  • Tarveda Therapeutics, Watertown, MA

  • Boston Medical Center, Boston, MA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroendocrine tumors

Biomarkers

  • Dystrophia myotonica1 protein kinase

Drug/Treatment

  • Somatostatin

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02936323

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved